Integral Health Asset Management LLC Has $17.92 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Integral Health Asset Management LLC raised its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 400,000 shares of the company's stock after buying an additional 75,000 shares during the period. Crinetics Pharmaceuticals comprises 1.7% of Integral Health Asset Management LLC's investment portfolio, making the stock its 17th largest position. Integral Health Asset Management LLC owned 0.51% of Crinetics Pharmaceuticals worth $17,916,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CRNX. Price T Rowe Associates Inc. MD grew its stake in shares of Crinetics Pharmaceuticals by 27.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,823,218 shares of the company's stock valued at $178,966,000 after buying an additional 814,360 shares in the last quarter. Vanguard Group Inc. grew its position in Crinetics Pharmaceuticals by 2.1% in the first quarter. Vanguard Group Inc. now owns 3,575,076 shares of the company's stock valued at $167,349,000 after acquiring an additional 72,624 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Crinetics Pharmaceuticals by 10.6% during the first quarter. Jennison Associates LLC now owns 2,817,854 shares of the company's stock valued at $131,904,000 after purchasing an additional 270,171 shares during the period. First Light Asset Management LLC lifted its position in shares of Crinetics Pharmaceuticals by 25.5% during the fourth quarter. First Light Asset Management LLC now owns 1,987,772 shares of the company's stock worth $70,725,000 after purchasing an additional 404,443 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Crinetics Pharmaceuticals by 264.1% in the first quarter. Janus Henderson Group PLC now owns 1,978,172 shares of the company's stock valued at $92,526,000 after purchasing an additional 1,434,909 shares during the period. 98.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CRNX has been the topic of several analyst reports. JMP Securities reaffirmed a "market outperform" rating and set a $80.00 price target on shares of Crinetics Pharmaceuticals in a research note on Tuesday, June 4th. Cantor Fitzgerald reiterated an "overweight" rating and set a $90.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Monday, September 16th. JPMorgan Chase & Co. lifted their target price on Crinetics Pharmaceuticals from $47.00 to $54.00 and gave the company an "overweight" rating in a research note on Tuesday, July 9th. Piper Sandler reissued an "overweight" rating and set a $97.00 price target on shares of Crinetics Pharmaceuticals in a report on Tuesday, July 2nd. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $73.00 price objective (down previously from $74.00) on shares of Crinetics Pharmaceuticals in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $68.55.

Insider Activity

In related news, COO Jeff E. Knight sold 956 shares of Crinetics Pharmaceuticals stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $44.38, for a total value of $42,427.28. Following the transaction, the chief operating officer now owns 52,580 shares of the company's stock, valued at approximately $2,333,500.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Marc Wilson sold 32,129 shares of the firm's stock in a transaction on Friday, June 28th. The stock was sold at an average price of $43.61, for a total value of $1,401,145.69. Following the completion of the sale, the chief financial officer now owns 111,092 shares of the company's stock, valued at $4,844,722.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jeff E. Knight sold 956 shares of Crinetics Pharmaceuticals stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $44.38, for a total value of $42,427.28. Following the transaction, the chief operating officer now owns 52,580 shares in the company, valued at approximately $2,333,500.40. The disclosure for this sale can be found here. Insiders sold a total of 143,551 shares of company stock valued at $7,155,329 over the last three months. Insiders own 6.00% of the company's stock.

Crinetics Pharmaceuticals Trading Down 5.1 %

Shares of NASDAQ CRNX traded down $2.73 during midday trading on Monday, reaching $50.42. The company's stock had a trading volume of 766,757 shares, compared to its average volume of 790,065. The company has a market cap of $3.98 billion, a price-to-earnings ratio of -13.67 and a beta of 0.63. Crinetics Pharmaceuticals, Inc. has a one year low of $25.35 and a one year high of $55.78. The company has a 50 day moving average price of $52.40 and a 200 day moving average price of $48.05.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.08). The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.47 million. The business's revenue was down 59.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.94) EPS. Research analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.